ctrl K

Enliven Therapeutics Inc. (ELVN)

NASDAQ: ELVN · Real-Time Price · USD

18.65

-0.26 (-1.37%)

At close: Apr 29, 2025, 3:59 PM

Enliven Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017
Revenue	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Cost of Revenue	n/a	297K	622K	99K	97K	33K	n/a	n/a
Gross Profit	n/a	-297K	-622K	-99K	-97K	-33K	n/a	n/a
Operating Income	-104.55M	-83.53M	-38.79M	-24.76M	-9.32M	-24.12M	-10.68M	-8.9M
Interest Income	14.89M	11.97M	1.13M	22K	31K	578K	n/a	n/a
Pretax Income	-89.26M	-71.58M	-37.66M	-24.74M	-18.97M	-23.46M	-11.34M	221K
Net Income	-89.02M	-71.58M	-37.75M	-24.72M	-18.93M	-23.46M	-11.34M	n/a
Selling & General & Admin	23.78M	18.95M	7.77M	4.29M	1.08M	5.07M	2.44M	987K
Research & Development	80.78M	64.57M	31.02M	20.47M	8.24M	19.01M	8.24M	7.92M
Other Expenses	n/a	n/a	n/a	n/a	-9.68M	n/a	n/a	n/a
Operating Expenses	104.55M	83.53M	38.79M	24.76M	9.32M	24.08M	10.68M	8.9M
Interest Expense	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Selling & Marketing Expenses	n/a	n/a	n/a	n/a	n/a	-33K	n/a	n/a
Cost & Expenses	n/a	83.53M	38.79M	24.76M	9.32M	24.12M	10.68M	8.9M
Income Tax Expense	-232K	n/a	88K	-22K	-31K	653K	-821.14K	221K
Shares Outstanding (Basic)	47.07M	35.55M	6.25M	7.81M	3.48M	4.32M	4.32M	4.32M
Shares Outstanding (Diluted)	47.07M	35.55M	6.25M	7.81M	3.48M	4.32M	4.32M	4.32M
EPS (Basic)	-1.89	-2.01	-6.03	-3.17	-14.14	-5.43	-2.62	n/a
EPS (Diluted)	-1.89	-2.01	-6.03	-3.17	-14.14	-5.43	-2.62	n/a
EBITDA	-104.55M	-81.93M	-38.58M	-24.65M	-9.27M	-23.43M	-11.34M	221K
EBIT	n/a	-82.23M	-38.79M	-24.76M	-9.32M	-23.46M	-11.34M	221K
Depreciation & Amortization	n/a	297K	215K	115K	97K	33K	-660K	n/a